BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 21267790)

  • 1. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.
    Thompson SK; Sullivan TR; Davies R; Ruszkiewicz AR
    Ann Surg Oncol; 2011 Jul; 18(7):2010-7. PubMed ID: 21267790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
    König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
    Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.
    Li JW; Chuang TC; Yang AH; Hsu CK; Kao MC
    Int J Oncol; 2005 Apr; 26(4):933-43. PubMed ID: 15753987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
    Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
    BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers.
    Bizari L; Borim AA; Leite KR; Gonçalves Fde T; Cury PM; Tajara EH; Silva AE
    Cancer Genet Cytogenet; 2006 Feb; 165(1):41-50. PubMed ID: 16490596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
    Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens.
    Lesnikova I; Lidang M; Hamilton-Dutoit S; Koch J
    APMIS; 2009 Oct; 117(10):737-45. PubMed ID: 19775342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
    Liu W; Zhong S; Chen J; Yu Y
    J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
    JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
    Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS
    Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the HER2 amplification status in oesophageal adenocarcinoma by conventional and automated FISH: a tissue microarray study.
    Prins MJ; Ruurda JP; van Diest PJ; van Hillegersberg R; ten Kate FJ
    J Clin Pathol; 2014 Jan; 67(1):26-32. PubMed ID: 24043715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
    Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
    Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study.
    Prins MJ; Ruurda JP; van Diest PJ; van Hillegersberg R; Ten Kate FJ
    Ann Oncol; 2013 May; 24(5):1290-7. PubMed ID: 23334118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.
    Shousha S; Peston D; Amo-Takyi B; Morgan M; Jasani B
    Histopathology; 2009 Jan; 54(2):248-53. PubMed ID: 19207950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.
    Minner S; Jessen B; Stiedenroth L; Burandt E; Köllermann J; Mirlacher M; Erbersdobler A; Eichelberg C; Fisch M; Brümmendorf TH; Bokemeyer C; Simon R; Steuber T; Graefen M; Huland H; Sauter G; Schlomm T
    Clin Cancer Res; 2010 Mar; 16(5):1553-60. PubMed ID: 20179235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
    Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.
    Marx AH; Burandt EC; Choschzick M; Simon R; Yekebas E; Kaifi JT; Mirlacher M; Atanackovic D; Bokemeyer C; Fiedler W; Terracciano L; Sauter G; Izbicki JR
    Hum Pathol; 2010 Nov; 41(11):1577-85. PubMed ID: 20656317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.